Vaxcyte, Inc. (PCVX) Q3 2025 10-Q Quarterly Report
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Vaxcyte, Inc. (PCVX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Vaxcyte, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Delays in drug substance manufacturing campaign due to Lonza capacity constraints impacting VAX-24 IND timelines
- • Updated financial risk: Net losses $212.8M Q3 2025 vs $103.1M Q3 2024; accumulated deficit $1.9B as of September 30, 2025
Vaxcyte, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$213M
▼ -106.4% YoY▼ -27.8% QoQ
ROE
-7.4%
Total Assets
$3.2B
EPS (Diluted)
$-1.57
▼ -89.2% YoY▼ -28.7% QoQ
Operating Cash Flow
-$143M
▼ -136.1% YoY▼ -18.3% QoQ
Source: XBRL data from Vaxcyte, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vaxcyte, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.